These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24983368)

  • 1. Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing.
    Patton S; Normanno N; Blackhall F; Murray S; Kerr KM; Dietel M; Filipits M; Benlloch S; Popat S; Stahel R; Thunnissen E
    Br J Cancer; 2014 Jul; 111(2):413-20. PubMed ID: 24983368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of the First Italian External Quality Assurance Scheme for somatic EGFR mutation testing in non-small-cell lung cancer.
    Normanno N; Pinto C; Taddei G; Gambacorta M; Castiglione F; Barberis M; Clemente C; Marchetti A
    J Thorac Oncol; 2013 Jun; 8(6):773-8. PubMed ID: 23575414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme.
    Marchetti A; Barberis M; Papotti M; Rossi G; Franco R; Malatesta S; Buttitta F; Ardizzoni A; Crinò L; Gridelli C; Taddei GL; Clemente C; Scagliotti G; Normanno N; Pinto C
    J Thorac Oncol; 2014 Oct; 9(10):1470-6. PubMed ID: 25170637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment.
    Deans ZC; Bilbe N; O'Sullivan B; Lazarou LP; de Castro DG; Parry S; Dodson A; Taniere P; Clark C; Butler R
    J Clin Pathol; 2013 Apr; 66(4):319-25. PubMed ID: 23378269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples.
    Keppens C; Dequeker EMC; Rouleau E; 't Hart N; Bubendorf L; Dufraing K; Garrec C; Guéguen P; Lamy A; Marchetti A; Pauwels P; Ryska A; Tack V; Tornillo L; Van Casteren K; von der Thüsen JH; Zwaenepoel K; Lissenberg-Witte B; Thunnissen E; Schuuring E
    BMC Cancer; 2020 May; 20(1):366. PubMed ID: 32357863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a worldwide external quality assessment of cfDNA testing in lung Cancer.
    Fairley JA; Cheetham MH; Patton SJ; Rouleau E; Denis M; Dequeker EMC; Schuuring E; van Casteren K; Fenizia F; Normanno N; Deans ZC
    BMC Cancer; 2022 Jul; 22(1):759. PubMed ID: 35820813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
    Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
    Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.
    Normanno N; Pinto C; Castiglione F; Fenizia F; Barberis M; Marchetti A; Fontanini G; De Rosa G; Taddei GL
    J Transl Med; 2015 Sep; 13():287. PubMed ID: 26335936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial.
    Fassunke J; Ihle MA; Lenze D; Lehmann A; Hummel M; Vollbrecht C; Penzel R; Volckmar AL; Stenzinger A; Endris V; Jung A; Lehmann U; Zeugner S; Baretton G; Kreipe H; Schirmacher P; Kirchner T; Dietel M; Büttner R; Merkelbach-Bruse S
    Virchows Arch; 2017 Oct; 471(4):509-520. PubMed ID: 28884371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.
    Hofman P; Calabrese F; Kern I; Adam J; Alarcão A; Alborelli I; Anton NT; Arndt A; Avdalyan A; Barberis M; Bégueret H; Bisig B; Blons H; Boström P; Brcic L; Bubanovic G; Buisson A; Caliò A; Cannone M; Carvalho L; Caumont C; Cayre A; Chalabreysse L; Chenard MP; Conde E; Copin MC; Côté JF; D'Haene N; Dai HY; de Leval L; Delongova P; Denčić-Fekete M; Fabre A; Ferenc F; Forest F; de Fraipont F; Garcia-Martos M; Gauchotte G; Geraghty R; Guerin E; Guerrero D; Hernandez S; Hurník P; Jean-Jacques B; Kashofer K; Kazdal D; Lantuejoul S; Leonce C; Lupo A; Malapelle U; Matej R; Merlin JL; Mertz KD; Morel A; Mutka A; Normanno N; Ovidiu P; Panizo A; Papotti MG; Parobkova E; Pasello G; Pauwels P; Pelosi G; Penault-Llorca F; Picot T; Piton N; Pittaro A; Planchard G; Poté N; Radonic T; Rapa I; Rappa A; Roma C; Rot M; Sabourin JC; Salmon I; Prince SS; Scarpa A; Schuuring E; Serre I; Siozopoulou V; Sizaret D; Smojver-Ježek S; Solassol J; Steinestel K; Stojšić J; Syrykh C; Timofeev S; Troncone G; Uguen A; Valmary-Degano S; Vigier A; Volante M; Wahl SGF; Stenzinger A; Ilié M
    ESMO Open; 2023 Oct; 8(5):101628. PubMed ID: 37713929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Causes behind error rates for predictive biomarker testing: the utility of sending post-EQA surveys.
    Keppens C; Schuuring E; Dequeker EMC
    Virchows Arch; 2021 May; 478(5):995-1006. PubMed ID: 33225398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization.
    Tembuyser L; Tack V; Zwaenepoel K; Pauwels P; Miller K; Bubendorf L; Kerr K; Schuuring E; Thunnissen E; Dequeker EM
    PLoS One; 2014; 9(11):e112159. PubMed ID: 25386659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer.
    Pirl WF; Traeger L; Greer JA; Bemis H; Gallagher E; Lennes I; Sequist L; Heist R; Temel JS
    Oncologist; 2011; 16(9):1299-306. PubMed ID: 21807767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid biopsy for detection of EGFR T790M mutation in nonsmall cell lung cancer: An experience of proficiency testing in Taiwan.
    Ho HL; Huang CC; Ku WH; Ho CL; Lin CH; Yu SL; Chou TY
    J Chin Med Assoc; 2019 Jun; 82(6):473-476. PubMed ID: 30932938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience and outcome of 3 years of a European EQA scheme for genetic testing of the spinocerebellar ataxias.
    Seneca S; Morris MA; Patton S; Elles R; Sequeiros J
    Eur J Hum Genet; 2008 Aug; 16(8):913-20. PubMed ID: 18301445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.
    Ellison G; Zhu G; Moulis A; Dearden S; Speake G; McCormack R
    J Clin Pathol; 2013 Feb; 66(2):79-89. PubMed ID: 23172555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR mutation testing practice in advanced non-small cell lung cancer.
    Bar J; Cyjon A; Flex D; Sorotsky H; Biran H; Dudnik J; Peylan-Ramu N; Peled N; Nechushtan H; Gips M; Katsnelson R; Rosenberg SK; Merimsky O; Onn A; Gottfried M
    Lung; 2014 Oct; 192(5):759-63. PubMed ID: 24964874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Routine implementation of EGFR mutation testing in clinical practice in Flanders: 'HERMES' project.
    Janssens A; De Droogh E; Lefebure A; Kockx M; Pauwels P; Germonpre P; van Meerbeeck JP
    Acta Clin Belg; 2014 Apr; 69(2):92-7. PubMed ID: 24724747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.